X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to assess the compatibility of Emergex’s immunotherapeutic candidates, including EMX-001 (dengueTcP) with the DEKA Intradermal Therapeutic Applicator.
Lead Product(s): DengueTcP
Therapeutic Area: Infections and Infectious Diseases Product Name: EMX-001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Emergex Vaccines Holding
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 16, 2024
Details:
Under the terms of the agreement, DEKA and Zealand will develop a medical pump system that is suitable for use in combination with dasiglucagon. DEKA and its affiliates will be responsible for pump development and pump manufacturing activities.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Zealand Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 05, 2021
Details:
Remodulin (treprostinil) is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Remodulin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: United Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
